3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Dermatologic
1
Conditions
Lymphoma, T-Cell, Cutaneous
2
Lymphoma, T-Cell
2
Lymphoma, Non-Hodgkin
2
Lymphoma, T-Cell, Peripheral
1
Lymphoma, B-Cell
1
Leukemia, Myeloid, Acute
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hematologic Neoplasms
1
Breast Neoplasms
1
Interventions
Cytarabine
272
Cyclophosphamide
136
fludarabine phosphate
127
Azacitidine
117
Peripheral Blood Stem Cell Transplantation
95
Busulfan
93
Filgrastim
80
Decitabine
79
fludarabine
78
Mycophenolic Acid
78
Idarubicin
76
Etoposide
76
Whole-Body Irradiation
75
Daunorubicin
72
Tacrolimus
71
Cyclosporine
64
Methotrexate
62
Mitoxantrone
57
Clofarabine
55
Antilymphocyte Serum
55
Granulocyte Colony-Stimulating Factor
51
Gemtuzumab
50
Melphalan
49
venetoclax
48
Radiotherapy
30
sargramostim
28
Injections
25
Bortezomib
25
thymoglobulin
24
aldesleukin
24
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Leukemia, Myeloid, Acute
×
tenalisib
×
Clear all
NCT02017613
2016-06-24
PI3K
Rhizen Pharmaceuticals SA
Phase 1
Completed
35 enrolled